Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:~1. Age 18-80 at screening (or minimum age of consent according to local regulations).~2 Chronic AD (also known as atopic eczema) that was diagnosed at least 1 year prior to Screening and meets Hanifin and Rajka criteria at screening).1 3. Moderate to severe AD:~1. IGA score ≥3 (on the 0 to 4 IGA scale, in which 3 = moderate and 4 = severe) at screening and baseline (Day 1)~2. BSA ≥10% of AD involvement at screening and baseline (Day 1)~3. Eczema Area and Severity Index (EASI) ≥16 at screening and baseline (Day 1) 4. A participant who has failed a prior systemic therapy for AD, ie, refractory, moderate-to-severe AD that is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.~   5. Willing to apply a topical emollient/moisturizer at least once daily for ≥1 week prior to baseline (Day 1) and willing to maintain consistent (ie, no change in type, frequency, or application) daily application over the course of the study.~   Exclusion Criteria:~   Participants are excluded from the study if any of the following criteria apply:~   Medical Conditions:~  1. Presence of confounding factors:~      * Skin conditions (eg, psoriasis, seborrheic dermatitis) that may interfere with evaluation of AD or assessment of treatment response as deemed by the investigator.~     * Current significant active infection or requiring a treatment for infection that may interfere with the assessment of AD.~  2. Hypersensitivity to etrasimod or any of the excipients.~  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- etrasimod (Type: EXPERIMENTAL): 2 mg, oral tablet, once daily
- Placebo (Part 1 DB period only) (Type: PLACEBO_COMPARATOR): Oral sham comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).